<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with Alzheimer’s disease constitute a special subgroup due to their vulnerability and their inability to communicate adverse events, in later stages of the disease. This population needs special attention with respect to the monitoring of adverse effects and drug–drug interactions. Hence, there is a need to integrate pharmacovigilance of herbal medicines with that of the modern medicine, under the national pharmacovigilance programs.</p>
